

LIFE HEALTHCARE GROUP HOLDINGS LIMITED

(Incorporated in the Republic of South Africa)

Registration number: 2003/002733/06

Income tax number: 9387/307/15/1

ISIN: ZAE000145892

Share code: LHC

("Life Healthcare" or "the Company" or "the Group")

8 June 2021

Update regarding Life Molecular Imaging following the approval of Biogen's aducanumab

Life Healthcare welcomes the US Food and Drug Administration's (FDA) decision, announced on 7 June 2021, to grant accelerated approval of aducanumab for the treatment of Alzheimer's disease. This decision is significant, given that c.35 million people suffer from Alzheimer's disease globally. Continued approval relies on the demonstration of clinical benefit in confirmatory trials.

Aducanumab has been shown to reduce amyloid beta plaques in the brain which is likely to slow neurodegeneration and disease progression. It is the first drug approved to treat Alzheimer's disease in 20 years.

This approval marks an exciting moment in Life Molecular Imaging's (LMI) journey from the a research and development arm within the Bayer Pharma AG's laboratories, to the work continued by the Piramal family over the past 20 years ago.

Before achieving EBITDA breakeven in 2020, over \$400 million had been invested in this business to research, and develop, a pipeline of radioisotope tracers to assist with the diagnosis of various diseases. One such tracer, LMI's FDA-approved Beta amyloid imaging tracer NeuraCeq®, is used to diagnose Alzheimer's disease by highlighting the Beta amyloid deposits in the brain. Aducanumab's approval yesterday paves the way for LMI to become an integral part of the diagnostic pathway, prior to patients starting treatment for Alzheimer's disease.

"At Life Healthcare, our purpose is making life better - for patients and our people. As we expand and grow our business into new markets, our purpose will become increasingly important to more people in more geographies. Having a part to play in improving the lives of Alzheimer's patients and bringing hope to them and their families is significant and aligned to our purpose. It's about making life better for all," says Peter Wharton-Hood, Group Chief Executive for Life Healthcare.

LMI has the capability to manufacturer NeuraCeq® through its wholly-owned cyclotrons across Europe. In partnerships with cyclotron operators, LMI will also scale up investment to bolster its manufacturing capacity for NeuraCeq® whilst also enhancing its sales, marketing and distribution capabilities.

This is also an exciting moment for LMI's parent company, Alliance Medical Group (AMG), one of the largest diagnostic imaging groups within Europe. AMG is well placed to assist patients undergoing diagnostic testing for Alzheimer's disease through its network of PET-CT scanners. In addition, AMG can assist with the MRI scans that patients on aducanumab may need as part of the monitoring of their treatment.

LMI and AMG are delighted to be able to leverage their vertically integrated business models to assist with the diagnostic and subsequent treatment pathway to patients with cognitive illnesses.

At this stage, the financial impact of the FDA approval is uncertain due to a numbers of factors. Shareholders will be kept updated as and when further clarity is obtained.

About Life Healthcare Group

Life Healthcare Group is a global, people-centred, diversified healthcare organisation with over 33 years' experience in the South African private healthcare sector, currently operating 66 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, and employee health and wellness services. The Group owns Alliance Medical Group, the leading independent provider of medical imaging services within Europe. Visit www.lifehealthcare.co.za

About Life Molecular Imaging

Life Molecular Imaging (LMI, formerly Piramal Imaging) was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. It is now part of the Alliance Medical Group (a member of the Life Healthcare Group) offering an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. By developing novel PET tracers for molecular imaging, LMI is focusing on a key field of modern medicine. The organization strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. Visit <https://life-mi.com>.

About Alliance Medical Group

Alliance Medical is a leading diagnostic imaging services provider in the United Kingdom and western Europe. The Group combines service excellence and innovative imaging technologies to improve patient care and support public and private healthcare organisations with their medical imaging requirements. Alliance Medical offers an integrated diagnostic imaging business that includes research and development laboratories, a network of cyclotrons and imaging facilities, which are revolutionising our approach to diagnosis and treatment of a range of conditions, such as Alzheimer's disease, dementia/ neurodegeneration, oncology and cardiovascular disease. Visit www.alliancemedical.com

For further information, please contact:
Mark Wadley, Head of Investor Relations
investor.relations@lifehealthcare.co.za

Sponsor

RAND MERCHANT BANK (A division of FirstRand Bank Limited)